Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
44,495 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy.
Peng Q, Wong YC, Cheng WY, He Y, Xie C, Shi Y, Wang T, Du Y, Yang X, Wang Z, Wang H, Lu H, Chen Z, Jin X, ICVAX Phase I clinical trial study team. · J Infect Dis · 2026 · cited 1 timesclinical trial, phase i, randomized controlled trial
- Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections.
deCamp AC, Juraska M, Li L, Magaret CA, Williamson BD, Bai H, Huang Y, Giorgi EE, Zhang L, Carpp LN, Edupuganti S, Mgodi NM, Gillespie K, Haddock B, Gonzales P, Cabello R, Orrell C, Lama JR, Laher F, Lazarus EM, Sanchez J, Frank I, Hinojosa JC, Sobieszczyk ME, Mukwekwerere PG, Makhema J, Baden LR, Seaton KE, Hural J, McElrath MJ, Takuva S, Randhawa AK, Kochar N, Piwowar-Manning E, Donnell DJ, Sista N, Andrew P, Karuna ST, Kublin JG, Gray GE, Cohen MS, Barouch DH, Tomaras GD, Rolland M, Montefiori DC, Morris L, Mullins JI, Williamson C, Corey L, Gilbert PB. · Sci Transl Med · 2026 · cited 0 timesrandomized controlled trial
- Systematic Review and Meta-Analysis of Genome-Wide CRISPR-Cas Screens to Identify Host Factors Involved in HIV-1 Infection.
Zhu M, Sun Z, Xu K, Ye L. · Viruses · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
Rockstroh JK, Ramgopal MN, Curran Fàbregas A, Hedgcock M, Workowski KA, Ronot-Bregigeon S, Cassetti I, Brinson C, Gupta SK, Hung CC, O'Reilly M, Slim J, Gatanaga H, Shalit P, Liu SY, Klopfer SO, Shihadeh F, Patel N, Mercier RC, Shaughnessy M, Dvory-Sobol H, SenGupta D, Llamoso C, Rhee MS, Orkin C, ISLEND-1 Study Team. · N Engl J Med · 2026 · cited 9 timesclinical trial, phase iii, equivalence trial
- Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents With HIV-1 in IMPAACT P1093 and IMPAACT 2019.
McKenna M, Lulic Z, Buchanan AM, Brothers C, Tan LK, Wang M, Brummel S, Ziemba L, Ruel T, Flynn PM, Rabie H, Wiznia A. · J Pediatric Infect Dis Soc · 2026 · cited 0 timesOpen accessclinical trial, phase ii, clinical trial, phase i
- HIV-1 Drug Resistance Mutations in Children: A Systematic Review of Global Genotypic Evidence (2014-2026).
Jouf G, Alami AB, Maazaz N, Benchekroun S, Elharti E, Belbacha I, Ihazmad H, Jaoudi RE, Benhida R, Rchiad Z, Oumzil H. · Pathogens · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Reservoir differences across HIV-1 subtypes: a systematic review to guide cure research.
Willemsen MS, Tanja AAN, Munsaka S, Nakanjako D, Ndung'u T, Papathanasopoulos MA, Jenniskens K, Sinatti G, Symons J, Wensing AMJ, Nijhuis M, Rozhnova G. · Front Immunol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Efficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.
M Alghzawi H, Shah SZ, Abideen ZU, Ashraf MF. · HIV Res Clin Pract · 2026 · cited 1 timesmeta-analysis, systematic review
- Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment.
Abdeldayem MR, Elsherbeeny A, Beddor A. · Eur J Clin Pharmacol · 2026 · cited 1 timesmeta-analysis, systematic review
- Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral Load.
Vaidya TR, Geib T, Lalezari JP, Bettacchi C, Brinson CC, Ruane PJ, Betman H, Zhou F, Krishnan P, Mostafa NM. · J Infect Dis · 2026 · cited 0 timesOpen accessclinical trial, phase i, randomized controlled trial
- Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.
Theodore DA, Mayer BT, Rolle CP, DeJesus E, Ackerman ME, Seaman MS, Weiner JA, Mohri H, Huang Y, Gray B, Chang J, Gerber MW, Yu J, Luo Y, Padte NN, Yin MT, Barin B, Greene R, Palmer S, Pazmino A, Benitez J, Dorr C, McNairy M, DiRenzo J, Orzell CV, Ho DD, Hyrien O, Sobieszczyk ME. · Nat Med · 2026 · cited 2 timesOpen accessclinical trial, phase i, randomized controlled trial
- B/F/TAF in people with both HIV-1 and hepatitis B: outcomes from the ALLIANCE open-label extension phase.
Avihingsanon A, Leong CL, Hung CC, Kiertiburanakul S, Lee MP, D'Antoni ML, Madera S, Wang H, Hindman JT, Li T. · AIDS Res Ther · 2026 · cited 0 timesOpen accessclinical trial, phase iii, randomized controlled trial
- First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial.
Rosen EP, Bondoc S, Bailón L, Blay L, Caballero A, García-Guerrero MC, Puertas MC, Moraes-Cardoso I, Vazquez-Escobales A, Blanco J, Mothe B, Kashuba AD, Estes JD, Martinez-Picado J, Molto J, DUALITY study group. · Nat Commun · 2026 · cited 0 timesOpen accessrandomized controlled trial, research support, n.i.h., extramural
- Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL).
Palich R, Lê MP, Castagna A, Allavena C, Antinori A, Canetti D, Tiraboschi J, Duvivier C, Martinez E, Domingo P, Barkat S, Dudoit Y, Béniguel L, Peytavin G, Marcelin AG, Soulié C, Assoumou L, Katlama C, DORAL Study Group , on behalf of. · J Antimicrob Chemother · 2026 · cited 0 timesclinical trial, phase ii, multicenter study
- Quantifying how HIV-1 envelope sequence features impact vaccine efficacy in the HVTN 705/HPX2008 randomised trial in southern African women.
Juraska M, Li L, Magaret CA, Peng J, Giorgi EE, Ludwig J, Carpp LN, deCamp AC, Kee JJ, Molitor C, Mandig M, Edlefsen PT, Rossenkhan R, Westfall DH, Deng W, Chen L, Zhao H, Galvao B, Adams C, Yssel A, Matten D, York T, Gwashu-Nyangiwe A, Ndabambi N, Thebus R, Swann EM, Hural JA, van Duijn J, Buchbinder S, Tomaka F, Corey L, Mngadi K, Gray GE, Gilbert PB, Williamson C, Mullins JI. · EBioMedicine · 2026 · cited 0 timesOpen accessrandomized controlled trial
- VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines.
Khaitan A, Lindsey JC, Capparelli EV, Tierney C, Coletti A, Perlowski C, Yin DE, Smith MEB, Spiegel HML, Majji S, Moye J, Gama L, Koup RA, Lin BC, McDermott AB, Purdue L, Krotje C, Harding PA, Cotton MF, Costello D, Petropoulos CJ, Reeves JD, Mallewa M, Chihana R, Kamthunzi P, Mbengeranwa TG, Masheto G, Santos Cruz ML, Pilotto JH, Ponatshego PL, Persaud D, McFarland EJ, IMPAACT 2008 Team. · Sci Transl Med · 2026 · cited 0 timesrandomized controlled trial
- Characterisation of HIV-1 Gag Cytotoxic T-Lymphocyte Epitopes in the Southern African Region-A Systematic Review.
Fortuin TL, Nkone P, Loubser S, Tiemessen CT, Mayaphi SH. · Immunology · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Safety and pharmacokinetics of CL-197, a potent compound with low cytotoxicity against HIV-1: a randomized, double-blind, placebo-controlled, first-in-human phase 1 clinical trial.
Guo Y, Li Y, Zhao P, Bi J, Gou C, Chuai Z, Yu S, Zhang R, Du J, Ou Y, Xu R, Guo N, Wang F-S, Li Y. · Antimicrob Agents Chemother · 2026 · cited 0 timesOpen accessclinical trial, phase i, randomized controlled trial
- VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment.
Ghosn J, Pulido F, Lopardo GD, Olczak A, Ripamonti D, Martin C, Paredes Ceballos O, Stocker H, Mendez Vazquez MJ, Gatanaga H, Metallidis S, Elbirt D, Whitlock G, Mateo González JI, Mohammed P, Wang K, Grove R, Wang R, Jewell A, Sutton K, Elliot E, Moodley R, Borsi R, Jones B, Kisare M, Budnik P, van Wyk J, VOGUE Study Group, VOGUE Study Group . · Open Forum Infect Dis · 2026 · cited 0 timesOpen accessclinical trial
- CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers.
Levy Y, Moog C, Wiedemann A, Launay O, Candotti F, Hardel L, Durand M, Hejblum BP, Rieux V, Diallo A, Lacabaratz C, Cardinaud S, Zurawski S, Zurawski G, Tomaras GD, Ding S, Centlivre M, Thiebaut R, Pantaleo G, Lelièvre JD, Richert L, ANRS VRI06 Study Group. · Sci Rep · 2026 · cited 0 timesOpen accessmulticenter study, clinical trial, phase i
- MVA.HIVconsvX vaccination-evoked T cell expansion inversely associates with age in people with HIV-1 on antiretroviral therapy.
Gay CL, Xu Y, Weideman AMK, Shaw FR, Kuruc JD, Conrad SZ, Mariano SA, Samir S, Kallon S, Sponaugle AT, Warren JA, Clutton GT, Abad-Fernandez M, Kapper C, Bradley AB, Baker CE, Pedersen SM, Moeser MJ, Burke L, Wee EG, Crook A, Laird GM, Cyktor JC, Mellors JW, Zhou S, Fox L, Eron JJ, Margolis DM, Hudgens MG, Hanke T, Goonetilleke N. · J Clin Invest · 2026 · cited 0 timesOpen accessresearch support, non-u.s. gov't, randomized controlled trial
- Surveillance of HIV-1 drug resistance in Tanzania across the pre- and post-dolutegravir eras: A systematic review and meta-analysis.
Njiro BJ, Bwire GM. · J Infect Public Health · 2026 · cited 0 timesmeta-analysis, systematic review
- Correlates of HIV-1 control after combination immunotherapy.
Peluso MJ, Sandel DA, Deitchman AN, Kim SJ, Dalhuisen T, Tummala HP, Tibúrcio R, Zemelko L, Borgo GM, Singh SS, Schwartz K, Deswal M, Williams MC, Hoh R, Shimoda M, Narpala S, Serebryannyy L, Khalili M, Vendrame E, SenGupta D, Whitmore LS, Tisoncik-Go J, Gale M, Koup RA, Mullins JI, Felber BK, Pavlakis GN, Reeves JD, Petropoulos CJ, Glidden DV, Spitzer MH, Gama L, Caskey M, Nussenzweig MC, Chew KW, Henrich TJ, Yukl SA, Cohn LB, Deeks SG, Rutishauser RL. · Nature · 2026 · cited 57 timesOpen accessclinical trial, research support, n.i.h., extramural
- Efficacy of dolutegravir/lamivudine in adults with HIV-1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results.
Fox D, Slim J, Overton ET, Doblado-Maldonado A, Jeffery P, Grove RA, Advani SD, Borsi R, Parry CM, Underwood M, Jones B. · HIV Med · 2026 · cited 1 timesOpen accessclinical trial, phase iii, brief-report
- Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Through the Open-Label Extension of the ALLIANCE Study.
D'Antoni ML, Boopathy AV, Andreatta K, Chang S, Hindman JT, Avihingsanon A, VanderVeen LA, Callebaut C. · J Acquir Immune Defic Syndr · 2025 · cited 0 timesclinical trial, phase iii, multicenter study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.